ProCE Banner Activity

The Evolving Role of VEGF Targeted Agents in Treating Solid Tumors

Slideset Download
Download these slides to review the most recent data informing optimal use of VEGFR-targeted TKIs in treating patients with solid organ tumors, then use the slides in your own presentations.

Released: November 15, 2019

Expiration: November 13, 2020

No longer available for credit.

Share

Faculty

Tanios Bekaii-Saab

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Richard S. Finn

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Tanios Bekaii-Saab, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Leader
Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Phoenix, Arizona

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania